# ZYNYZ (retifanlimab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/retifanlimab

> ZYNYZ (retifanlimab), sponsored by INCYTE CORP (INCY), received a complete response letter from the FDA; the decision is dated February 27, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is ZYNYZ (retifanlimab) FDA approved?

Not as of November 16, 2026. ZYNYZ (retifanlimab), sponsored by INCYTE CORP (INCY), received a complete response letter from the FDA; the decision is dated February 27, 2026. SEC Form 8-K: "On February 27, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the supplemental Biologics License Application ("sBLA") for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer ("NSCLC") in combination with platinum-based chemotherapy." [Calendar and source filings](https://sec-api.dev/pdufa/retifanlimab)

Source: SEC Form 8-K, accession 0000879169-26-000013, https://www.sec.gov/Archives/edgar/data/879169/000087916926000013/incy-20260227.htm (retrieved 2026-11-12). Last confirmed 2026-03-06. Cite: https://sec-api.dev/pdufa/retifanlimab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ZYNYZ (retifanlimab) |
| Codes | INCMGA0012, INCMGA00012, MGA012 |
| Sponsor | INCYTE CORP (INCY) https://sec-api.dev/companies/incy/catalysts |
| Indications | with metastatic or recurrent locally advanced merkel cell carcinoma |
| Modality | antibody |
| FDA designations | accelerated |

## Timeline

### Mar 2023: FDA approval

- Status: completed, approved. Date confidence: month. Indication: with metastatic or recurrent locally advanced Merkel cell carcinoma.
- First seen 2025-02-10, last confirmed 2025-07-29.
- SEC Form 10-Q (accession 0000879169-25-000103): "In March 2023, we announced that the FDA had approved ZYNYZ (retifanlimab-dlwr) under accelerated approval, for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm
- SEC Form 10-Q (accession 0000879169-25-000056): "In March 2023, we announced that the FDA had approved ZYNYZ (retifanlimab-dlwr) under accelerated approval, for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)." https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm
- SEC Form 10-K (accession 0001628280-25-004633): "In March 2023, we announced that the FDA had approved ZYNYZ (retifanlimab-dlwr) under accelerated approval, for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)." https://www.sec.gov/Archives/edgar/data/879169/000162828025004633/incy-20241231.htm

### Jul 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-02-10, last confirmed 2025-07-29.
- SEC Form 10-Q (accession 0000879169-25-000103): "In July 2024, we announced positive topline results from both the two Phase 3 clinical studies evaluating retifanlimab, a humanized monoclonal antibody targeting programmed cell death receptor-1 (PD-1), in SCAC and NSCLC." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm
- SEC Form 10-Q (accession 0000879169-25-000056): "In July 2024, we announced positive topline results from both the two Phase 3 clinical studies evaluating retifanlimab, a humanized monoclonal antibody targeting programmed cell death receptor-1 (PD-1), in SCAC and NSCLC." https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm
- SEC Form 10-K (accession 0001628280-25-004633): "In July 2024, we announced positive topline results from both the two Phase 3 clinical studies evaluating retifanlimab, a humanized monoclonal antibody targeting programmed cell death receptor-1 (PD-1), in SCAC and NSCLC." https://www.sec.gov/Archives/edgar/data/879169/000162828025004633/incy-20241231.htm

### February 27, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-03-06, last confirmed 2026-03-06.
- SEC Form 8-K (accession 0000879169-26-000013): "On February 27, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the supplemental Biologics License Application ("sBLA") for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer ("NSCLC") in combination with platinum-based chemotherapy." https://www.sec.gov/Archives/edgar/data/879169/000087916926000013/incy-20260227.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/retifanlimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ZYNYZ (retifanlimab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/retifanlimab

```bibtex
@misc{secapidev_pdufa_retifanlimab_20261116,
  title        = {ZYNYZ (retifanlimab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/retifanlimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_retifanlimab_20261116","title":"ZYNYZ (retifanlimab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/retifanlimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
